Enjoy complimentary customisation on priority with our Enterprise License!
There is a rising need for efficacious therapeutics that can either slow or reverse the progression of the lysosomal storage disease (LSD). The available medicines in the market are ineffective to improve neurological symptoms associated with LSDs due to the limited penetration of blood brain barrier. Technavio’s market study identifies this unmet need for effective treatment as one of the primary growth factors for the lysosomal storage diseases market. In addition to this, the high cost of treatment will also contribute to the growth of the market. Our market research analysts estimate that this market will grow steadily at a CAGR of more than 7% by 2021.
Several legislative changes are aimed to promote research and development activities for rare diseases in the developing economies. Increasing awareness of the importance of orphan drug designations in these developing regions is encouraging the development of regulatory protocols. Pharmaceutical manufacturers in the developing countries are also focusing extensively on the research and development of novel therapeutics. This industry research report identifies the increase in regulatory assistance in emerging nations as one of the key trends that will contribute to the growth of the lysosomal storage diseases market.
The lysosomal storage diseases market is highly consolidated due to the presence of a few key vendors who account for the major market share. The key vendors compete intensely based on factors such as product pipeline, emerging indications/applications, and collaborations. The competition among the vendors in the lysosomal diseases market will intensify in the coming years due to product portfolio expansions and the development of novel therapeutics using emerging technologies.
End users primarily prefer enzyme replacement therapy (ERT) therapy as ERT contains targeted therapies that are efficient and effective for treating LSDs. Additionally, ERT also provides high efficacy and is administered through intravenous infusion where they metabolize the accumulated substrate effectively.
In EMEA, the rising awareness about the treatment of rare diseases, government initiatives to encourage orphan drug development, and favorable regulatory policies contribute to the growth of the lysosomal storage diseases market. Additionally, the availability of favorable reimbursement policies in Europe will also contribute to the growth of the lysosomal diseases market in the region.
Want a bigger picture? Try a FREE sample of this report now!
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research methodology
PART 04: Introduction
PART 05: Understanding LSDs
PART 06: Pipeline
PART 07: Market landscape
PART 08: Market segmentation by therapy
PART 09: Market segmentation by geography
PART 10: Decision framework
PART 11: Drivers and challenges
PART 12: Trends
PART 13: Vendor landscape
PART 14: Key vendor analysis
PART 15: Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.